{"gao_id": "GAO-20-626T", "published": "2020-06-02T12:00:00Z", "released": "2020-06-02T08:00:00Z", "summary": "The outbreak of COVID-19 has called greater attention to the United States\u2019 reliance on foreign drug manufacturers. Much of the drug manufacturing for the U.S. market happens overseas\u2014and drugs for treating COVID-19 are no exception. Food and Drug Administration inspections of foreign and domestic drug manufacturers are critical to ensuring drug safety and effectiveness. But FDA began to postpone almost all inspections of foreign manufacturing...", "title": "Drug Safety: COVID-19 Complicates Already Challenged FDA Foreign Inspection Program", "topics": ["Drug safety", "Public health emergencies", "Manufacturing", "Compliance oversight", "Foreign drug manufacturing", "User fees", "Supply chain management", "Foreign drug inspection", "Health Care", "Prescription drugs", "Drugs"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-20-626t", "versions": [{"title": "Highlights Page (2 pages)", "url": "https://www.gao.gov/assets/gao-20-626t-highlights.pdf"}, {"title": "Full Report (31 pages)", "url": "https://www.gao.gov/assets/gao-20-626t.pdf"}, {"title": "Accessible PDF (34 pages)", "url": "https://www.gao.gov/assets/710/707372.pdf"}]}